Outcome of Idiopathic Pulmonary Fibrosis With Pregnancy

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

Outcome of Idiopathic Pulmonary Fibrosis With Pregnancy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04775277
• Other study ID #: Soh-Med-21-02-38
• Status: Completed
• Start date: December 1, 2018
• Est. completion date: February 20, 2021

Study information

• Verified date: February 2021
• Source: Sohag University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

case-control study was conducted between December 2018 to April 2020. To document outcome of IPF with pregnancy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: February 20, 2021
• Est. primary completion date: April 30, 2020
• Gender: Female
• Age group: 18 Years to 38 Years

Eligibility

Inclusion Criteria:

• Patients with pulmonary diseases during pregnancy

Exclusion Criteria:

• Patients with pulmonary diseases other than IPF and bronchial asthma were excluded.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
Egypt	Sohag University	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. Review. Erratum in: Am J Respir Crit Care Med2002 Aug 1;166(3):426. — View Citation

Sharma CP, Aggarwal AN, Vashisht K, Jindal SK. Successful outcome of pregnancy in idiopathic pulmonary fibrosis. J Assoc Physicians India. 2002 Nov;50:1446-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	any adverse events including gestational complication or disease specific complication	e.g (development of respiratory failure, need for ICU admission). maternal outcome	from the start of inclusion to the study till termination of pregnancy, average 9 months period
Primary	neonatal outcome	any unfavorable neonatal outcome as low birth weight	December 2018 to April 2020
Primary	neonatal outcome	any unfavorable neonatal outcome as prematurity or neonatal death.	December 2018 to April 2020